Evidence map›Paper›PMID 40242450›Full record

ArticleFrontiers in pharmacology2025

Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways.

Chenglong Guo, Tianxing Zhang, Lingqian He, Minyu Zhang, Yanyan Chu, Xipeng Sun, Xuexue Han, Yijiang Liu, Juexian Song, Jinggang Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chenglong Guo *Pulmonary Vascular Disease Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Tianxing Zhang *Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Lingqian He *Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Minyu ZhangSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Yanyan ChuDepartment of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Xipeng SunDepartment of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Xuexue HanDepartment of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Yijiang LiuSenior Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Juexian SongDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Jinggang XiaDepartment of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Inflammation is a key driver of adverse outcomes in acute myocardial infarction (AMI), yet current western anti-inflammatory therapies are limited by their single-target nature and side effects. Traditional Chinese medicine (TCM), such as Tanhuo Decoction (THD), offers a multi-target, low-toxicity alternative. Methods: In a randomized controlled trial, AMI patients with high inflammatory responses received either standard Western medicine (WM) alone or combined with THD for 3 days. Clinical outcomes and inflammatory markers were assessed, and proteomic and network pharmacology analyses were performed. Results: The THD + WM group showed significant reductions in neutrophil counts and hs-CRP levels, along with improved creatinine clearance rate (CCR), compared to WM alone. Proteomic analysis revealed downregulation of pro-inflammatory proteins (PTX3, IL-18, TNFRSF11A) and upregulation of the anti-inflammatory IL1RL2. THD also modulated lipid metabolism and insulin sensitivity pathways. Discussions: THD enhances the anti-inflammatory and metabolic benefits of standard AMI therapy through multi-target pathway regulation. These findings support its integration into modern cardiovascular care, particularly for patients with high inflammatory and metabolic risk.

Indexed as

acute myocardial infarctioncardiorenal protectioninflammationmetabolismTanhuo decoction

Identifiers

PMID40242450
PMCPMC12000776

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.